Gapping up
In reaction to earnings/guidance:
- SOFI +6.4%, PK +4.1%, EHTH +2.7% (guidance), KBR +2.7%, L +2.2%, NCLH +2.2%
Other news:
- ISEE +18% (to be acquired by Astellas for $40 per share in cash)
- ASND +17.4% (FDA issues complete response letter for TransCon PTH in hypoparathyroidism)
- JSPR +3.8% (files $250 mln mixed shelf securities offering)
- JPM +3.5% (JPMorgan Chase (JPM) acquires substantial majority of assets and assumes certain liabilities of First Republic Bank)
- LI +3.4% (April deliveries)
- ARQT +3.3% (Announces Canadian Approval of ZORYVE)
- MLCO +2.6% (Macau gaming revs)
- WYNN +2.4% (Macau gaming revs)
- LVS +2.1% (Macau gaming revs)
- IMTX +2.1% (announced that Bristol Myers Squibb (BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy candidate from their ongoing collaboration)
- NIO +0.9% (April deliveries)
- XPEV +0.9% (April deliveries)
Analyst comments:
- ALHC +4.8% (upgraded to Outperform from Mkt Perform at Raymond James)
- BIRD +4% (upgraded to Outperform from Market Perform at Telsey Advisory Group)
- ZG +1.8% (upgraded to Mkt Perform from Underperform at Bernstein)
- CMCSA +1.1% (upgraded to Buy from Neutral at BofA Securities)